Experts say virtual health care could fill gaps in the Dehcho. Some residents aren’t so sure - CBC

Skip to Main ContentAccessibility HelpMenuCBC GemCBC ListenSearchQuick LinksNewsSportsRadioMusicListen LiveTVWatchnewsTop StoriesLocalClimateWorldCanadaPoliticsIndigenousBusinessThe NationalHealthEntertainmentScienceCBC News InvestigatesDisability LifeGo PublicAbout CBC NewsBeing Black in CanadaVideoThis Fort Simpson org wants wildfire relief program for Dehcho businesses | CBC.ca LoadedThis Fort Simpson org wants wildfire relief program for Dehcho businessesOctober 2|Duration 1:34October 2NewsDuration 1:34closed captionThe Dehcho Business Development Centre is asking for $1 million that it could distribute to all affected businesses in the region, with different levels of funding depending on the size of the business and on the impact. Related StoriesFort Simpson organization pushes for relief funds for businesses impacted by wildfiresDene Nation reports small surplus, still dealing with $1M deficitYellowknife’s downtown business owners explain what ‘revitalization’ would look likeYukon, federal gov’ts say new health care funding on the wayAs wildfire season winds down, people in B. C.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.